Topoisomerase II α and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas

Chinese Journal of Pathology

Volumn 36, Issue 2, 2007, Pages 102-106

  Liang, Zhi Yong ^a   Wang, Wen Ze ^a   Gao, Jie ^a   Wu, Sha Fei ^a   Zeng, Xuan ^a   Liu, Tong Hua ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

DNA topoisomerases, type II; In situ hybridization, fluorescence; Pancreatic neoplasms; Receptor, erbB 2

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROTO ONCOGENE;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, PANCREATIC DUCTAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 34047160947     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer, 2006, 13(1):39-49.
2. Flaherty KT, Brose MS. Her-2 targeted therapy: beyond breast cancer and trastuzumab. Curr Oncol Rep, 2006, 8(2):90-95.
3. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II α gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res, 2002, 8(5): 1107-1116.
4. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II a associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol, 2000, 156(3):839-847.
5. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase II α predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res, 2002, 8(4):1061-1067.
6. Park K, Kim J, Lim S, et al. Topoisomerase II α(topo II) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer, 2003, 39(5):631-634.
7. Bauman ME, Holden JA, Brown KA, et al. Differential immunohistochemical staining for DNA topoisomerase II α and β in human tissues and for DNA topoisomerase II β in non-Hodgkin's lymphomas. Mod Pathol, 1997, 10(3):168-175.
8. Hansel DE, Ashfaq R, Rahman A, et al. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase II α and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening and treatment. Am J Clin Pathol, 2005, 123(1):28-35.
9. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol, 2002, 160(4):1239-1249.
10. Mueller R, Parkes R, Anndrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II α protein in human breast tumor samples. Genes Chromosomes Cancer, 2004, 39(4):288-297.
11. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates of breast carcinomas. Cytopathology, 2003, 14(6):314-321.
12. Varis A, Wolf M, Monni O, et al. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res, 2002, 62(9): 2625-2629.
13. Wikman H, Kettunen E, Seppaen JK, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene, 2002, 21(37):5804-5813.
14. Guerin E, Entz-Werle N, Eyer D, et al. Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia, 2003, 17(3):532-540.
15. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer, 2003, 107 (5):764-772.
16. Burris HA 3rd, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997, 15(6):2403-2413.
17. Buchler P, Reber HA, Buchler MC, et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg, 2001, 5(2):139-146.
18. Thybusch-Bernhardt A, Aigner A, Beckmann S, et al. Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo. Eur J Cancer, 2001, 37(13):1688-1694.
19. Wei S, Liang Z, Gao J, et al. Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing. J Gastroenterol Hepatol, 2005, 20(1):67-72.
20. Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer, 2004, 39(4):288-297.